Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Feb 18;14(4):e035478.
doi: 10.1161/JAHA.124.035478. Epub 2025 Feb 14.

Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves

Ghadeer K Dawwas  1 , James D Lewis  2   3 , Adam Cuker  4
Affiliations
Comparative Study

Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves

Ghadeer K Dawwas et al. J Am Heart Assoc. .

Abstract

Background: Despite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), data on patients with AF and valvular heart disease remain scarce. We aimed to evaluate the DOACs compared with warfarin among patients with AF and valvular heart disease.

Methods and results: We conducted a retrospective cohort study of patients ≥18 years of age, who had AF and valvular heart disease, and were new users of DOACs or warfarin. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety. We used Cox proportional-hazards regression after propensity score matching to estimate hazard ratios (HRs) and 95% CIs. In the matched cohort, DOAC use (versus warfarin) was associated with a lower rate of ischemic stroke or systemic embolism (HR, 0.70 [95% CI, 0.61-0.81]) and bleeding (HR, 0.72 [95% CI, 0.65-0.80]). We found a lower rate of ischemic stroke or systemic embolism with rivaroxaban (HR, 0.74 [95% CI, 0.62-0.89]) and apixaban (HR, 0.62 [95% CI, 0.52-0.74]) but not dabigatran (HR, 0.89 [95% CI, 0.63-1.26]). We found a lower rate of bleeding with rivaroxaban (HR, 0.84 [95% CI, 0.74-0.95]), apixaban (HR, 0.60 [95% CI, 0.53-0.68]), dabigatran (HR, 0.75 [95% CI, 0.58-0.97]), and edoxaban (HR, 0.21 [95% CI, 0.05-0.83]). We were unable to obtain estimates for the effectiveness outcome with edoxaban due to the small number of events.

Conclusions: In this study of patients with AF and valvular heart disease, DOAC treatment was associated with a lower risk of ischemic stroke or systemic embolism and bleeding compared with warfarin.

Keywords: anticoagulants; atrial fibrillation; effectiveness; safety; valvular heart disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative incidence curves depicting the rate for stroke or systemic embolism (A) and bleeding (B) in matched cohorts of patients with atrial fibrillation and valvular heart disease who were new users of DOACS or warfarin.
Horizontal lines represent the cumulative incidence over follow‐up time for DOACs and warfarin. P value obtained from stratified log‐rank test. d indicates days; and DOACs, direct oral anticoagulants.
See this image and copyright information in PMC

Comment in

References

    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375. doi: 10.1001/jama.285.18.2370 - DOI - PubMed
    1. Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In‐hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011;42:3214–3218. doi: 10.1161/STROKEAHA.110.610881 - DOI - PubMed
    1. Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic burden of stroke disease: a systematic review. Int J Environ Res Public Health. 2021;18:7552. doi: 10.3390/ijerph18147552 - DOI - PMC - PubMed
    1. Dawwas GK, Cuker A, Rothstein A, Hennessy S. Trends in post‐discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019. J Stroke Cerebrovasc Dis. 2022;31:106700. doi: 10.1016/j.jstrokecerebrovasdis.2022.106700 - DOI - PubMed
    1. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population‐based cohort study. Ann Intern Med. 2021;174:910–919. doi: 10.7326/M20-6194 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources